Overview

A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia

Status:
NOT_YET_RECRUITING

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

This is an open-label, randomized feasibility trial in which patients admitted to Oregon Health \& Science University (OHSU) after a pregnancy complicated by preeclampsia who are considering a progestin-only pill contraception postpartum will be randomized to norethindrone or drospirenone for 6 weeks following hospital discharge.

Phase:

PHASE4

Details

Lead Sponsor:

Oregon Health and Science University

Treatments:

drospirenone
Norethindrone